Zealand Pharma:
Press Release – No. 53 / 2020
Zealand Pharma to participate in upcoming investor conferences
Copenhagen, DK November 10, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in November:
Bryan, Garnier & Co European Healthcare Conference
Date: Monday, November 16, 2020
Jefferies Virtual London Healthcare Conference
Date: Tuesday, November 17, 2020
Fireside chat: 10:15 a.m. ET/ 3:15 p.m. GMT/ 4:15 p.m. CET
Nordea Innovation Seminar
Date: Wednesday, November 25/26, 2020
A live webcast of the Jefferies event will be available on the "Events & Presentations" page in the Investor section of the Company's website at . A replay of the webcast will be archived on the Company's website following the presentation.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit .
For further information, please contact:
Mads Kronborg
Head of Investor Relations & Communication
Phone:
Email:
For U.S. Media
David Rosen
Argot Partners
Phone: 212-600-1902
Email:
